Altimmune, Inc. recently unveiled compelling data from its 48-week Phase 2 MOMENTUM clinical trial, which evaluated the efficacy and safety of pemvidutide, a novel GLP-1/glucagon dual receptor agonist, in treating obesity. The results, presented during an oral session at the prestigious American Diabetes Association’s 84th Scientific Sessions, included a comprehensive body composition analysis that provided valuable insights into the potential of pemvidutide as a groundbreaking treatment option for individuals struggling with obesity.
The MOMENTUM trial showcased pemvidutide’s ability to promote significant weight loss and improve overall body composition, offering hope for millions of people affected by obesity worldwide. As Altimmune continues to advance its research and development efforts, the medical community eagerly anticipates further progress in the fight against the global obesity epidemic.